The overall prognosis can be improved by EGFR mutations testing and using the EGFR-TKI therapy early, as the chemotherapy has limited efficacy in NSCLC patients (Zhang et al., 2016). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.